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ABSTRACT 
Background: The influence of cigarette smoking in mental health has not been 
entirely studied yet. However, sleep disturbance is an established cause of mental 
illness. This review aims to provide an overview of previous investigations on 
cigarette smoking and its effect on sleep, and use it as an evidence of its influence on 
central nervous system. 
Methods: Using Pubmed as database we selected articles written (1) in English, 
(2) published after 1997 and (3) stating the relationship between “sleep” and 
“cigarette smoking” or “sleep” and “nicotine” as main subject.  
Results: Outcomes from 33 selected articles were organized according to the 
different ways in which cigarette smoking can affect sleep and allowed us to establish 
a correlation between subjective sleep complaints and objective sleep disturbance. 
Smokers not only seem to have daytime sleepiness more frequently but also less total 
sleep time, longer latency to sleep onset, and an altered polysomnography pattern 
(decrease of slow wave sleep, a extension of REM sleep latency, an increase of α-
frequencies and reduction of δ-frequencies), comparing to non-smokers. Most of these 
alterations can also be founded in non-smokers after administration of 24-hour 
nicotine patches (absence of acute withdrawal) and after exclusion of any kind of 
breathing disorder. 
Conclusion: Sleep disturbance in smokers is manly caused by direct influence of 
nicotine in sleep-wake cycle neurons. Further investigations targeting a better 
understanding of how nicotine could affect neural basis of behaviour and biological 
rhythms are needed. 
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RESUMO 
Introdução: A possível influência do tabaco na saúde mental dos fumadores ainda 
não foi totalmente esclarecida. Já os distúrbios de sono, são uma causa conhecida de 
doença mental. Esta revisão procura dar uma visão geral da literatura prévia à cerca 
de como o tabaco pode afetar o sono, e usar essa evidência como prova de que este 
tem impacto no equilíbrio do Sistema Nervoso Central.  
Métodos: Usando a Pubmed como base de dados, foram selecionados artigos 
escritos (1) em Inglês, (2) publicados depois de 1997 e (3) onde a relação entre 
“sono” e “fumadores” ou “sono” e “nicotina” aparecesse como principal tema do 
trabalho.  
Resultados: Os resultados dos 33 artigos selecionados foram organizados de 
acordo com as diferentes vias de como o tabaco pode afectar o sono e permitiram-nos 
estabelecer uma relação entre as queixas subjetivas e as alterações objectivas do sono 
nos fumadores. Os fumadores para além de referirem sintomas como sonolência 
diurna, mais frequentemente, também apresentam uma diminuição do tempo total de 
sono, maior latência para adormecer e ainda uma padrão de registo polissonográfico 
alterado (com diminuição de sono de ondas lentas, um aumento da latência para 
iniciar sono REM, um aumento de frequências α e diminuição de frequências δ), 
quando comparados com indivíduos não fumadores. A esmagadora maioria destas 
alterações foi também encontrada aquando a administração de pensos de nicotina de 
libertação prolongada (24 horas) em não fumadores (impossibilitando a existência de 
efeito agudo de abstinência) e após a exclusão de distúrbios respiratórios, que 
pudessem pôr em causa, por si só, a continuidade do sono. 
Conclusão: As alterações do sono em fumadores são principalmente causadas pelo 
efeito direto da nicotina nos neurónios reguladores do sono. Futuramente, devem ser 
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levados a cabo estudos que procurem esclarecer a influência da nicotina nos circuitos 
neuronais relacionados com o comportamento e o ritmo biológico. 
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IMPLICATIONS 
Despite being a controversial topic, sleep disturbance in smokers is consistently 
reported in the literature. However, information regarding this subject has been poorly 
discussed in a comprehensive manner and this investigation aims to fill that gap. This 
report aims to not only summarise the state of the art, but also to point out the 
mechanism that most likely explains how cigarette smoking affects sleep. In fact, the 
conclusions of our study may support a different course of action for physicians 
manage patients with insomnia combined with a nicotine addiction. It is also 
noteworthy the fact that nicotine affects sleep in a different pattern in depressed 
individuals. Further investigations regarding nicotine influence on patients with 
susceptibility for mental illness should be conducted.  
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INTRODUCTION 
Cigarette smoking is the most preventable cause of death in the world.  In the 20th 
century, the tobacco epidemic killed 100 million people worldwide. It mainly affects 
cardiovascular and respiratory systems.1 
Most of people are aware of the physical health risks of smoking tobacco, but 
usually have no idea of its association with mental health. There is no evidence that, 
in the long-term, heavy smoking leads to any kind of mental illness symptoms. But, 
on the other hand, we know that cigarette smoking is a very prevalent addiction in 
people with mental illness. Few studies have proved the existence of this association 
but it is still dubious whether smoking is a cause of mental disease or, otherwise, if 
people with mental problems are likely to become smokers.  
Using the U.S.A. as a statistical example (where 1 out of each 5 adults have some 
form of mental illness):  
-­‐ 36% of people with mental illness smoke, while only 21% of adults without 
mental illness do so;  
-­‐ 31% of all cigarettes are smoked by adults with mental illness; 
-­‐ 40% of men and 34% of women with mental illness smoke;  
-­‐ 48% of people with mental illness, who live below the poverty level, smoke, 
compared to 33% of those with mental illness who lived above the poverty level.2 
As any other drug of abuse, nicotine artificially improves our reward system and 
stimulates many others neural circuits in the brain. This could explain why people 
with mental health problems abuse tobacco in an effort to reduce their symptoms:  
-­‐ patients with schizophrenia may use nicotine to reduce cognitive deficits and 
negative symptoms or neuroleptic side effects. The prevalence of cigarette smoking 
amongst these subjects is still higher than in any other mental illness: 60-90% of 
patients with schizophrenia smoke.3 
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-­‐ patients with depression are twice more likely to be smokers. Nicotine 
stimulates the release of dopamine and serotonin, which is involved in triggering 
positive feelings. These neurotransmitters, like many others, are often found to be low 
amongst people with depression, who may then use cigarettes as a way of temporarily 
increasing their dopamine and serotonin supply. However, smoking encourages the 
brain to switch off its own mechanism for producing them so, in the long-term, the 
supply decreases, which in turn prompts people to smoke even more.4 
-­‐ patients with anxiety are also commonly smokers. Nicotine creates an 
immediate sense of relaxation so, people smoke believing that it reduces stress and 
anxiety, but this feeling is temporary and soon gives way to withdrawal symptoms 
and increased craving.4 
Most people start to smoke before they show signs of mental illness so, it remains 
unclear whether smoking leads to mental illness or mental illness encourages people 
to start smoking. The most likely explanation is that there is a complex relationship 
between the two. Although being hard to prove that cigarette smoking is a direct 
cause of major mental disorder, we cannot ignore the evidence of its influence upon 
the balance of Central Nervous System (CNS). One of the most significant proofs of it 
is how cigarette smoking affects sleep architecture. The correlation of it as an impact 
on mental health comes naturally.  
Evidence shows that sleep is essential to help maintaining the mood, memory, and 
cognitive performance. Sleep is a dynamic behavior, which consists in a special 
activity of the brain controlled by elaborate and precise mechanisms. Using these 
mechanisms, we depress few brain functions sequentially. Consequently, it is not a 
surprise that sleep problems may increase the risk of developing particular mental 
illnesses, as well as a result from such disorders.5 More recently, neuroimaging and 
neurochemistry studies suggest that a good night’s sleep helps foster both mental and 
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emotional resilience, while chronic sleep disruptions set the stage for negative 
thinking and emotional vulnerability.6 Last but not least, sleep disturbance can also 
affect physical health. Actually, sleep loss does far more than make us grumpy and 
groggy. It influences negatively our immune, cardiovascular and endocrine systems, 
as well as contributing to serious diseases such as obesity, diabetes, and hypertension.  
For instance, let’s take Americans as a sample population example. Actually, they 
represent industrialized society very well in this context. In a 2002 epidemiological 
study concerning sleep, 74% of respondents experienced at least one symptom of a 
sleep disorder a few nights a week or more.7 Concerning chronic sleep problems, 
these affect between 10% and 18% of adults in the general U.S. population.6 Despite 
this fact, more than 60% of adults have never been asked about the quality of their 
sleep by a physician, and fewer than 20% ever initiated a discussion about it.8 The 
latest research has shown that symptoms related to sleep are even more common 
among smokers when compared with the general population.  
Cigarette smoking can affect sleep through three different mechanisms:  
-­‐ nicotine can stimulate the release of several neurotransmitters that collectively 
participate in regulating the sleep-wake cycle;  
-­‐ regular smokers often experience acute withdrawal as the nicotine 
concentration in plasma is decreased during sleep;  
-­‐ smoke impact on airways can lead to sleep-related breathing disorders, such as 
apnea, whish consequently disrupt sleep continuity.  
Moreover, these hypothesized causal mechanisms are not mutually exclusive. In 
fact, some sleep disturbances may result from complex interactions among the 
stimulant effects of nicotine, nicotine withdrawal, and the respiratory effects of 
smoking. Based on that, this review aims to provide an overview of investigations on 
cigarette smoking and its effect on sleep. 
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METHODOLOGY 
Using Pubmed as database we started our search with the following query: 
("sleep"[MeSH] AND "smoking"[MeSH]). We got 446 articles. 
Then we used 2 additional filters: 
-­‐ articles written:  
1. in English; (410) 
2. after 1998, including; (279) 
After that, we analysed all abstracts of these 279 articles and used, as an excluding 
factor, the fact of that article doesn’t have the relation between “sleep” and “cigarette 
smoking” as a main subject. With that analysis we ended up with 21 articles. Three of 
them were rejected because the sample was not significant to our study (21-3=18).  
Then we realised that, few studies couldn’t use “cigarette smoking” terminology 
and instead of it, explore the specific effect of nicotine. Hence we made a second 
query: ("sleep"[MeSH] AND "nicotine"[MeSH]), and used the same additional filters: 
we got 54 articles. After using the same excluding factors as we did previously, we 
obtained a total of 20 articles. Five of them had appeared in previous search. 
Therefore, we conclude our search with 15 new articles to add to our research 
database, which ended up with a literary basis of 33 articles. 
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RESULTS 
The articles we found were heterogeneous, therefore we organized the information 
in reports according to their different contents. Based on this we will be able to write 
a more methodical discussion.   
Cigarette smoking is in fact a predictive factor for the development of sleep 
disturbances. However, tobacco is not usually the exclusive sleep-affecting habit in 
smokers: they also tend to make other unhealthy lifestyle choices, such as frequent 
use of alcohol and caffeine. On the other hand, the prevalence of self-reported 
cardiovascular and pulmonary disease was higher among current smokers than never 
smokers. A vast majority of the studies we selected tried to control these several 
confounding factors by performing a multivariate analysis. Finally, depression and 
use of psychotropic medication was also partly taken into account.9-14 All the 
summarised information in the next chapters presents statistically significant 
differences that were found.  
 
Epidemiology 
Sleep complaints 
Smokers have nearly double the risk of experiencing sleep disturbances, 
manifested primarily as difficulties falling asleep and daytime sleepiness. Thus, 
current smokers report greater difficulty than never smokers not only in initiating 
sleep, but also in maintaining it. Other symptoms of poor nocturnal sleep quality, 
including nocturnal awakenings, non-restorative sleep and difficulty in morning 
awakening are also more common in smokers.9,10,12,14-16 
Polysomnography pattern 
Even though subjective reports provide a convenient means for assessing sleep 
disturbance in field studies, they cannot characterize the range of physiologic 
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disturbances that may be detected with overnight polysomnography. Besides, current 
investigations show that the sleep architecture of smokers and non-smokers actually 
differs. Recent data have shown that smokers have less total sleep time (TST), lower 
sleep efficiency (ratio of total sleep time to the total amount of time spent in bed) and 
longer latency to sleep onset.9,10,17 
Tobacco also affects the pattern of sleep stages. Sleep pattern in smokers generally 
has:  
-­‐ increase of stage 1 and 2 with a concomitant decrease in slow wave sleep (SWS – 
formed by stage 3 and 4);9,10 
-­‐ extension of REM sleep latency;9,10,17 
-­‐ temporal alterations of REM sleep was not evident in any of the studies – see 
chapter “nicotine in sleep-wake cycle neuromodulation”);9,10,17,18 
-­‐ increase of α-frequencies and reduction of δ-frequencies, which is most 
pronounced at the beginning of the sleep period.9,10,17,18 
Cigarette smoking has also been related with alteration of activity during the day 
and of circadian rhythm, which is measured by a method called actigraphy. Actually, 
smoking is associated with less interdaily stability and more intradaily variability of 
the rhythm. Moreover, these variations typically occur in subjects who also have 
extended sleep onset latency and less total sleep time.12 
Former smoker vs Current smoker 
None of the studies showed significant differences between former and never 
smokers regarding sleep parameters. This suggests that smoking cessation can reverse 
the disturbances in nocturnal sleep.9 
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Etiopathology 
Nicotine in sleep-wake cycle neuromodulation 
Given the effects of nicotine on the central nervous system (CNS), the high 
prevalence of sleep disturbances in smokers is not surprising. Nicotine, the primary 
pharmacologically active component of cigarette smoke, acts centrally by stimulating 
nicotine-acetylcholine receptors. It does so by binding itself to the β2 subunit of the 
nAch receptors. These receptors are widely distributed in presynaptic neurons located 
in areas such as the anterior hypothalamus and the brainstem reticular formation. 
Activation of nicotinic receptors leads to the release of several neurotransmitters, 
including acetylcholine, dopamine, serotonin, norepinephrine, and gamma-amino 
butyric acid. The action of nicotine in sleep depends on interactive effects of these 
neurotransmitters on the central mechanisms that regulate the sleep-wake cycle, 
which can be delineated by oscillations between two opponent processes, one 
promoting sleep and the other promoting wakefulness.9,10,19,20 Studies in rats have 
shown that administration of mecamylamine (antagonist of nAch receptors) supresses 
the effects on sleep produced by nicotine.21 However, nicotine interferes with the 
sleep-wake cycle neuromodulation in a totally different way in non-REM sleep and 
REM sleep. 
Regulation of non-REM sleep depends on a decrease in aminergic neuronal 
activity within the locus coeruleus and dorsal ralph. By stimulating the release of 
aminergic neurotransmitters, nicotine may disturb the normal regulation of non-REM 
(NREM) sleep and shift the distribution of sleep architecture toward lighter stages of 
sleep. This extended state of arousal also explains the increase in sleep latency.9,10 
The ponto-geniculo-occipital (PGO) spikes, which are a specific characteristic of 
REM sleep in polysomnography in animals, are generated by cholinergic projections 
from pedunculo-pontine tegmental (PPT) and latero-dorsal (LDT) neurons. 
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Investigations in vivo have shown a dose-dependent suppression of the PGO spikes 
by nicotine. High levels of nicotine lead to stimulation of serotoninergic neurons of 
the dorsal raphe nucleus (DRN), which will have an inhibitory effect on LDT and 
PPT neurons.10 Studies in rats show that nicotine increases discharge in serotoninergic 
neurons in the DRN specifically during REM sleep. At least in the DRN, this 
discharge stimulated by nicotine, only has a statistically significant increment during 
REM sleep and NREM-REM sleep transition.22  
Additionally, studies have proved that nicotine inhibits sleep-promoting neurons in 
the ventrolateral preoptic area (VLPO) through a muscarinic postsynaptic action and 
nicotinic presynaptic action on noradrenergic terminals. This area, whose nucleus is 
located in the anterior hypothalamus, contains GABA, which is responsible for this 
mechanism of inhibition. These VLPO neurons constitute the majority of the 
projections to the dorsal raphe nucleus (DRN), the locus coeruleus and the 
interneurons of (LDT/PPT) region, so this can be related with the basis of neuronal 
circuit alterations described above.23,24 
We cannot forget that before the secondary regulation of REM sleep by 
serotoninergic neurons, the PGO spikes are generated by cholinergic neurons (located 
in the reticular formation21), which are directly sensible to nicotine action. Hence, 
studies also suggest that in lower doses, nicotine stimulates REM sleep. This might 
explain why alterations in REM-sleep in smokers are not consistent. Despite not been 
taken into account in all studies, it will always depend on the smoking status of each 
participant. In summary, data suggests dose-dependent effects of nicotine on REM 
sleep, i.e., lower doses stimulating REM sleep and higher doses supressing it.10  
This complex duality can explain why REM sleep alterations are not statistical 
significant in any of the studies. It would depend on the smoking status of each 
subject, which directly affects nicotine plasma levels before sleep.  
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Sleep apnea in smokers 
Sleep-related breathing disorders represent another possibility of how cigarette 
smoking affects sleep. There seems to be a synergistic effect between smoking and 
sleep apnea syndrome (SAS), causing increased cardiovascular morbidity combined, 
than each of them isolated.25 SAS is characterised by the interruption of breathing 
during sleep leading to a decrease of oxygen saturation. Occurrence of apnea leads to 
serious sleep fragmentation with frequent arousals and sleep stage changes and 
usually to daytime sleepiness.  
Prevalence of SAS among smokers is almost 40 times higher in smokers.10 It 
seems to be mainly caused by other substances in tobacco smoke other than nicotine 
(although one report describes a possible direct effect of nicotine in upper airway 
muscles26). There also seems to be an acute effect of these irritant substances on the 
pharynx mucosa. Actually, former smokers showed no increased risk of impaired 
breathing during sleep after controlling for other risk factors, such as coffee 
consumption, body mass index, etc.10,26,27 
Pathophysiology of SAS caused by cigarette smoke includes upper airway 
inflammation and decreased hypoxia sensitivity (which facilitates longer durations of 
apnea with saturation). This inflammation results in increased surface adhesive forces 
at the level of pharyngeal mucosa promoting upper airway collapse, obstruction and 
consequently snoring. Another explanation, could be the levels of plasma orexin-A, a 
neuropeptide involved in the regulation of food intake and the sleep-wake cycle, 
which is diminished in SAS patients and even more in SAS patients who 
smoke.10,20,26-29 Finally, when we only analyse studies where smoker participants with 
significant respiratory disturbances events were excluded, we realize that, in general, 
the main parameters of sleep pattern keep altered in the same way as others studies. 
For this reason, even though SAS influences sleep in smokers, it is not the most 
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significant cause of sleep disturbances in smoker population. 
Nicotine withdraw during sleep 
With sleep onset, blood nicotine levels gradually decrease and induce a state of 
nicotine withdrawal that can modify sleep continuity. This is obviously more 
preponderant when nicotine levels are higher during the day, which occurs among 
heavy smokers. Actually, few studies have observed nightly awakening due to 
nicotine craving in 20% of heavy smokers. Nevertheless, the arousals caused by 
craving would not be enough to wake up, but they still influence sleep architecture by 
subtle changes in temporal distribution of non-REM and REM sleep. 9,10 
 
Nicotine administration in healthy non-smokers 
Transdermal nicotine application in non-smokers results in a dose-dependent 
reduction of REM sleep, increased sleep stage 2, decreased TST with earlier 
awakening times and an increase in sleep latency. When nicotine is being 
administrated transdermally by 13-hour or 16-hour patches, instead of 24-hours 
patches, REM suppression is followed by a REM sleep rebound during withdrawal. 
This data is consistent with effects of smoked cigarettes, which supports the direct 
influence of nicotine in the CNS, which remains the main explanation to sleep 
disturbances in smokers. As a matter of fact, these studies show that nicotine 
administration was continuous and the participants were all non-smokers, hence none 
of them could feel nicotine withdrawal during night and the proportion of obstructive 
respiratory problems was equal between them and controls.10,30 
 
Sleep disturbance and cigarette abstinence 
Chronic tobacco consumption is usually coupled with physical and psychological 
dependence. Withdrawal symptoms include the craving for cigarettes, dysphoria, fear, 
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anhedonia, irritability or restless and increased appetite10,20,31 In addition to these 
depressive symptoms, there is sleep disturbance: insomnia complaints during nicotine 
withdrawal are reported in up to 39% cases.10 There are also few studies talking about 
a possible relationship between insomnia complaints and relapse rates.9,10,32,33 
Although subjective impairments of sleep during nicotine withdrawal were 
reported in all studies, polysomnography information did not consistently reproduce 
these findings and were contradicting regarding sleep duration, sleep efficiency, 
frequency of sleep stage changes and arousal frequency. This can be explained by the 
fact that sleep disturbance during withdrawal appears as a secondary effect of a state 
of depression. Similar to what happens in others kinds of depression, symptoms are 
very diverse among different subjects. No one feels depression the same way. 
Anyway, in most of the cases, this insomnia is temporary. Actually, the initial 
daytime sleepiness gradually decreased over 20 days. After 1 month, sleep 
architecture is comparable to the sleep of a never smoker.9,10 
In the particular case of heavy smokers, polysomnography data is more concordant 
with self-rating scales, i.e., in these cases, nicotine withdrawal has shown an increased 
sleep fragmentation.33,34 Some authors do indeed suggest that these patients, during 
smoking cessation, could benefit of a transition period provided by a transdermal 
nicotine patch that delivers nicotine to the blood at a slow constant rate through 
topical application on the skin. Specifically, the patches applied for 24-hour are more 
likely to protect against effects of abrupt nicotine withdrawal in sleep34-36 and to 
alleviating morning smoking urges.36 But even with 24-hour nicotine replacement 
therapy, the subjective complaints remain, probably related with a state of depression 
associated with a behavioral component of addiction (they are not using cigarette to 
get nicotine into plasma).34 Besides, if we use these patches in smokers who continue 
to smoke, that extra increment of nicotine, contrarily to the effect in smokers during 
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cessation process, results in an increase of sleep fragmentation.37 
 
Less sleep, more cigarettes – a vicious cycle 
Attention, decision-making and executive functioning are few examples of 
cognitive capacities, which are impaired by extended periods of wakefulness. On the 
other hand, during sleep deprivation, the nucleus accumbens becomes selectively 
more active. This area in the brain is not only responsible for the process of pleasure 
obtained in a present activity, but it is also involved with the anticipation of reward. 
Being selectively more active, it results in an elevation of the expectation of gains and 
a diminution of the effects of one’s losses following risky decisions. So, it seems 
logical that impaired attention and a deficit of inhibitory control combined, could 
increase cigarette smoking by smokers with sleep deprivation.  
In fact, a study suggests that sleep loss increases the likelihood of smoking during 
an abstinence period of 48h.  However, this increase was not related with measures of 
inhibition and attention. They concluded that sleep deprivation increases smoking, 
probably because smokers expect a decrease of sleepiness with it. Another possibility 
pointed by this study is that measures of impulsivity/inhibition weren’t sensitive 
enough to the effects of sleep deprivation and, therefore, increases of smoking 
through aspect of decision-making could not detected.38 Besides, impulsivity is much 
more complex to measure than self-reported fatigue.  
 
Sleep disturbance in depression – role of nicotine 
Sleep parameters of depressed patients are quite different from those of healthy 
individuals. They typically have decreased TST and sleep efficiency and significant 
decrements in stages 1, 3 and 4. Finally, total REM sleep duration is greater in 
depressed patients compared to healthy subjects, associated to a shortened REM sleep 
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latency. REM sleep disinhibition at the beginning of the night is one of the most 
frequently described biologic features of depressive disorders. This feature results 
from a cholinergic neuronal overactivity and also poor releases of serotonin by the 
dorsal ralph. As we already know, acetylcholine is a facilitator of REM-sleep, and 
serotonin, a neurotransmitter that is clearly diminished in depressed brains, is an 
inhibitor of REM-sleep.  
Two studies have shown that long-term administration of transdermal nicotine 
improve mood and sleep in depressed patients. This alteration seems to extend 
throughout the nicotine withdrawal period. Contrarily to healthy subjects (see chapter 
“Nicotine administration in healthy non-smokers”), nicotine administration in 
depressed people seems to improve sleep parameters such as an increment in REM 
sleep latency and an increased slow wave sleep, TST, and sleep efficiency.  
The increase in REM sleep latency was accompanied by a significant decrease in 
the score of the Hamilton rating scale for depression. Thus, nicotine in depression not 
only improves sleep, but also mood. Actually the two features seem to be etiologically 
related. Serotonin plays a modulatory role in sleep-wake cycle and mood. 
Tryptophan, a serotonin precursor, increases slow-wave sleep, reduces REM sleep 
and awake time during the night. Patients with major depression have a significant 
lower tryptophan/competing amino acids ratio than healthy individuals. So, it appears 
that major depression and related sleep disorders are associated with diminished 
serotonin synthesis in the brain. It is thus conceivable that nicotine’s action on sleep 
and mood is indirectly exerted through the serotonin system. The fact that during 
withdrawal of nicotine these patients maintained REM sleep latency values close to 
normal and showed sustained mood improvement may be related to equilibrium 
between cholinergic and serotoninergic activities. In the future, it would be of interest 
to determine if administration of transdermal nicotine modifies the actions of 
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antidepressants, and if it could be used in treatment-resistant depression.39,40 Actually, 
one of these studies shows an equivalent antidepressant efficacy between nicotine and 
fluoxetine,40 and a similar effect on sleep; however fluoxetine produces a greater 
increment in REM sleep latency.40,41 
We cannot forget that both studies were conducted with a small sample of non-
smokers and nicotine administration was going to be reduced along a few months and 
stopped after 9/10 months (depending on the study). By the way, this fact doesn’t 
contradict that depression in smokers doesn’t have a better outcome. We are just 
discussing an eventual benefice of temporary nicotine administration in the rebalance 
of neurotransmitters in depression.   
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DISCUSSION 
Although the influence of cigarette smoking in sleep is still very controversial, we 
have tried to focus on the most significant and concordant data that we found. 
Nonetheless, the complexity of the topic is not the only limitation. Most of the 
studies, at least the ones conducted with humans, did not take into account variables 
such as:  
-­‐ serum nicotine concentrations among subjects; 
-­‐ menstrual cycle in females; 
-­‐ precise smoking pattern (smoking status was based on self-report without 
corroborating objective documentation). 
It is clear now, that acetylcholine plays a role in regulating sleep, and all kinds of 
nicotine administration influences this control by stimulating nAch receptors. This 
direct influence is, in our point of view, the most preponderant way in which cigarette 
smoking affects sleep. As proof of that, main alterations of sleep found in smokers 
(such as decreased TST, increased REM sleep latency and sleep latency and less 
SWS) were concordant with changes found in studies where nicotine was 
administered continuously by patches in healthy subjects. On the other hand, 
differences found in electroencephalographic (EEG) activity between smokers and 
non-smokers were greatest in the early part of the sleep period. Facts that remove 
importance from the other two possible causes of how tobacco could affect sleep are: 
respiratory diseases (insignificant in healthy non-smokers groups) and nicotine 
withdrawal during the night (inexistent in a continuous nicotine administration). This 
influence is diminished in repeated administrations (studies in rats21) as we can see in 
chronic smokers (when comparing with acute administrations on healthy non-
smokers). Sleep modification should be attenuated by compensatory mechanisms 
triggered by chronic treatment. However, an absolute reverse can only take place after 
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a period of totally nicotine abstinence. This fact also reinforces the idea that sleep 
disturbance in smokers is mainly caused by direct influence of nicotine present in 
plasma, and once removed, the effect is over. At this point we can extrapolate few 
guides for practical medicine on two types of patients: 
-­‐ a smoker patient who suffers insomnia should be informed that tobacco has a 
harmful influence on sleep and should therefore be motivated to quit or reduce; 
-­‐ a smoker who wants to quit, should notice that he will probably experience 
insomnia, but it will be gradually diminished during the first month of abstinence 
and after that he will have a better sleep quality than he has as a smoker 
(reinforcing patient will). 
Like what happens in most of medical topics, “each case is a case”. Nicotine 
administration, even when temporary, is prejudicial to sleep architecture with 
practical consequences (for example: daytime sleepiness) in mental healthy subjects. 
On the other hand it could be useful to revert sleep disturbance in depressed patients. 
Anyway, we can now safely conclude that nicotine has a significant impact in neural 
circuits homeostasis, and sleep disturbance probably is just one single proof of many 
more. Finally, further investigations targeting a better understanding of how nicotine 
could affect neural basis of behaviour and biological rhythms are needed.  
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Acknowledgments, References. 
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and the number of references should not exceed 10. 
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2. Abstract 
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Investigations and Brief Report sections are: Introduction, Methods, Results, and 
Discussion. Use a maximum of three level headings. For example: 
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authors and then add “et al.”  
 
Include the DOI numbers for content published online ahead of print, when full 
issue pagination is not yet available. 
 
9. Tables 
Tables longer or wider than one published page will be included as online-only 
Supplementary Material accessed through the journal archive, but not published in the 
journal’s print or online PDF versions. Include tables at the end of the main manuscript, 
created in Word, using the table function. Follow these rules: 
• Do not create a table using only tabs or spaces to create columns.  
• Do not create a table in Excel and embed it in a Word document. If you 
export a table from Excel, import it into the Tables function and format it 
for Word.  
• Do not use features such as Word Art in tables.  
• Mention the tables in the main text, but do not note in the manuscript where 
tables and figures should be inserted.  
• Tables should not duplicate material contained in the main text. 
• Number the tables consecutively, as they should appear in the text.  
• Note: Do not note in the manuscript where tables and figures should be 
inserted, but refer to them as they relate to the text (for example: “Table 1 
lists the subject characteristics…” or “Group differences are depicted in 
Figure 2…”) 
• Note: For all experiments/analyses where appropriate (e.g., human 
laboratory studies, clinical trials, etc.), add a statement to the manuscript in 
the methods section confirming whether or not you have reported all 
measures, conditions, and data exclusions, as well as how sample sizes were 
determined. Provide detailed explanations, as needed. For more information, 
refer to the N&TR editorial on statistical reporting. 
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D. Submitting Figures and Supplementary Materials 
The instructions for preparing figures are also available here. Figures can be color or 
black/white. Figures published in color in the print version of the paper will incur a publishing 
cost to the authors. The following guidelines for figures are essential: 
 
1. File Formats 
The journal prefers that figures be created in Excel. If you create figures in a program such 
as SigmaPlot or CorelDraw, you must export the file as .TIF. Do not embed a figure file as a 
picture into Excel or Word. The typesetters can work with figures in the following formats: 
•  .TIF (Tagged Image Format File)  
• .DOC (Microsoft Word document)  
• .XLS (Microsoft Excel)  
• .PPT (Microsoft PowerPoint)  
• .PDF (Portable document format, Adobe)  
• .AI (Adobe Illustrator)  
• .WMF (Windows metafile)  
• .PNG (Portable Network Graphics) 
 
2. Figure Size 
Size the figure to the column or page width of the journal, and set the resolution at 300 dpi 
or greater. 
 
3. Microcharts 
The journal encourages the use of microcharts (also called sparklines) where appropriate. 
Microcharts can save considerable space and can include both data and a graphic element. 
Further guidelines on using microcharts can be found here.  
 
4. Follow the Instructions 
Figures must conform to the journal’s guidelines before a manuscript can be accepted and 
sent to production. Submitting figures in a nonpreferred format will delay or prevent 
publication.  
 
5. Order 
Number all figures consecutively, as they should appear in the text. 
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6. Supplementary Material 
Unpublished material such as tables and figures that relate to the manuscript but are too 
lengthy to be printed with the manuscript can be submitted online as Supplementary 
Material. These should be in a final, viewable format such as PDF, with any track-changes 
hidden. You will be able to upload this material when you submit your manuscript. Do not 
include material that has been published previously or is otherwise under copyright 
restriction. 
E. How to Upload Your Manuscript 
You will need to do the following when you submit your manuscript: 
 
1. Contact Information 
Provide contact information for all authors. 
 
2. Author Keywords 
If you are not in the online system’s database, you may need to provide keywords 
describing your areas of expertise. Use the pull-down list or enter your own terms. 
 
3. Corresponding Author 
Identify a corresponding author. You also can identify an alternate. 
 
4. Type of Submission 
Identify the type of manuscript you are submitting (see General Guide for 
descriptions and allowed size), along with the numbers of words, figures, and tables. 
 
5. Topic Keywords 
Identify keywords that apply to your manuscript. Use the pull-down list or enter your 
own terms. 
 
6. Verification 
Verify that the manuscript is the author's own work and is not under review, in press, 
or published elsewhere. Also verify that the manuscript meets ethical guidelines, 
including adherence to the legal requirements of the study country is performed. The 
journal considers plagiarism, including self plagiarism, a serious offense and the 
editors reserve the right to withdraw papers where there is evidence of plagiarism and 
to take appropriate action against the authors. Authors are directed to Chapter 5, 
section 4 (5.4), of the AMA Manual of Style for the definition of plagiarism that will be 
applied. 
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7. Authorship 
Verify that all authors qualify for authorship under the guidelines of the AMA Manual 
of Style, 10th Edition. This involves making a primary contribution and holding 
primary responsibility for the data, concepts, and interpretation of results. Authorship 
should include those who have made substantial scientific contributions to the study. 
 
8. Competing Interests 
Declare any competing interests for each author. For questions about what 
constitutes a competing interest, refer to our Declarations of Funding and Competing 
Interests statement. 
 
9. Registration of Clinical Trials 
If the paper reports the results of a clinical trial, authors should indicate whether or 
not the study has been preregistered. If the trial has been preregistered, authors must 
report the trial number and the preregistration authority/organization in the paper. 
 
10. Copyright Permission 
Identify any figures or other portions of the manuscript for which copyright 
permission is required. Authors are responsible for securing permission. For more 
information, please visit Oxford Journals Rights & Permissions. 
 
11. Supplementary Material 
Upload any supplementary material linked to the manuscript that will be viewed 
online-only. 
 
12. Themed or Special Issue 
Identify any supplement or dedicated issue for which the manuscript is being 
submitted. 
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13. Upload Files 
Upload separate manuscript files for the Main Document and the Figures (note that 
you can upload them in any order and reorder them using a pull-down menu; be sure 
to save the revised order).  
 
Before uploading, turn off Track Changes and accept all changes as a “Final” version 
(not “Final Showing Markup”). Do not select “Show Comments.” Articles with 
tracked changes and inserted comments will not be considered for publication until 
the authors remove those features. 
 
Your manuscript should be in any version of Microsoft Word for Windows or 
Macintosh, or WordPerfect for Windows.  
 
Your manuscript cannot be considered for publication until the figures are submitted 
in a viewable format.  
 
When you upload figures, you can add descriptive tags and comments. 
 
14. Check PDF 
Once the files are uploaded, click on the PDF link below them, to view the PDF. You 
must check the PDF at this stage or later in the submission process. 
F. The Peer Review Process 
After initial screening by an editor, all manuscripts submitted to the journal are rigorously peer 
reviewed single-blind.  
 
We now offer our reviewers the option to sign their reviews if they wish, in which case their 
name is disclosed to the study authors in the decision letter. 
 
N&TR does not normally use reviewers who are employed by companies that produce tobacco 
products. However, if there are special circumstances in which a handling editor judges that such 
a person may provide expertise that cannot be obtained from other reviewers, s/he may, with 
the permission of the authors, seek a review from that person. This review will be marked as 
from a tobacco industry employee in correspondence with the authors. These circumstances are 
expected to be extremely rare. 
G. Self-Archiving Policy 
This information is available on the journals Self-Archiving policy page. 
H.License to Publish Form 
Upon receipt of accepted manuscripts at Oxford Journals authors will be invited to complete an 
online copyright license to publish form. The journal encourages authors to complete their 
copyright license to publish form online. 
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Please note that by submitting an article for publication you confirm that you are the 
corresponding/submitting author and that Oxford University Press ("OUP") may retain your 
email address for the purpose of communicating with you about the article. You agree to notify 
OUP immediately if your details change. If your article is accepted for publication OUP will 
contact you using the email address you have used in the registration process. Please note that 
OUP does not retain copies of rejected articles. 
I. Open Access 
Authors have the option to publish their paper under the Oxford Open initiative, whereby, for a 
charge, their paper will be made freely available online immediately upon publication. After your 
manuscript is accepted, the corresponding author will be required to accept a mandatory licence 
to publish agreement. As part of the licensing process you will be asked to indicate whether or 
not you wish to pay for open access. If you do not select the open access option, your paper will 
be published with standard subscription-based access and you will not be charged. 
 
Oxford Open articles are published under Creative Commons licenses.  
 
RCUK/Wellcome Trust funded authors publishing in Nicotine & Tobacco Research can use the 
Creative Commons Attribution license (CC BY) for their articles. 
 
All other authors may use the following Creative Commons licences:  
Creative Commons Attribution Non-Commercial No Derivatives licence (CC BY-NC-ND) 
Please click here for more information about the Creative Commons licenses. 
 
Charges Information 
You can pay Open Access charges using our Author Services site. This will enable you to pay 
online with a credit/debit card, or request an invoice by email or post. The applicable Open 
Access charges vary according to which Creative Commons license you select. The Open Access 
charges are as follows. 
 
• Charges for CC BY:  
•Regular charge: £2297/ $3675 / €2986  
• Reduced Rate Developing country charge*: £1149/ $1838 / €1493  
• Free Developing country charge*: £0 /$0 / €0  
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• Charges for CC BY-NC-ND:  
• Regular charge: £1969/ $3150 / €2560 
• Reduced Rate Developing country charge*: £985/ $1575 / €1280  
• Free Developing country charge*: £0 /$0 / €0  
*Visit our Developing Countries page for a list of qualifying countries. 
Please note that these charges are in addition to any colour/page charges that 
may apply. 
 
Orders from the UK will be subject to the current UK VAT charge. For orders from the rest 
of the European Union, OUP will assume that the service is provided for business purposes. 
Please provide a VAT number for yourself or your institution, and ensure you account for 
your own local VAT correctly. 
J. Funding 
The following rules should be followed: 
 
An example is given here: ‘This work was supported by the National Institutes of Health (P50 
CA098252 and CA118790 to R.B.S.R.) and the Alcohol & Education Research Council (HFY 
GR667789).’ 
 
1. The sentence should begin: ‘This work was supported by …’ 
 
2. The full official funding agency name should be given, i.e. ‘the National Cancer 
Institute at the National Institutes of Health’ or simply 'National Institutes of Health', 
not ‘NCI' (one of the 27 subinstitutions) or 'NCI at NIH' (full RIN-approved list of 
UK funding agencies) . 
 
3.  Grant numbers should be complete, accurate, and provided in parentheses as 
follows: ‘(grant number xxxx)’  
 
4. Multiple grant numbers should be separated by a comma as follows: ‘(grant numbers 
xxxx, yyyy)’  
 
5. Agencies should be separated by a semi-colon (plus ‘and’ before the last funding 
agency). 
 
6. Where individuals need to be specified for certain sources of funding the following 
text should be added after the relevant agency or grant number 'to [author initials]'. 
 
Oxford Journals will deposit all NIH-funded articles in PubMed Central. See 
https://academic.oup.com/journals/pages/authors for details. Authors must ensure that 
manuscripts are clearly indicated as NIH-funded using the guidelines above. 
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Crossref Funding Data Registry 
In order to meet your funding requirements authors are required to name their funding sources, 
or state if there are none, during the submission process. For further information on this process 
or to find out more about the CHORUS initiative please click here. 
K. Journal Policies on Ethics 
1. Publication Ethics 
The journal adheres to the COPE guidelines in all matters relating to publication 
ethics. 
 
2. Animal & Human Experimentation 
All manuscripts reporting data obtained from animals or humans must have passed 
formal review and been given approval (or deemed exempt) by an appropriate 
institutional review board (IRB) or research ethics committee (REC), prior to 
conducting the research. This should be explicitly described in the Methods section of 
the manuscript. We may request documentation relating to the review process and 
approval from authors. 
Human studies should follow the ethical principles described in the Declaration of 
Helsinki. A description of how informed consent was obtained (e.g., written or oral), 
and whether participants were reimbursed for participation, should be provided in the 
Methods section. 
Animal experiments should comply with ARRIVE guidelines, and other appropriate 
guidelines, such as relevant EU Directives relating to animal experiments, and/or the 
National Institutes of Health guide for the care and use of laboratory animals. 
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L. Language Editing 
Language editing, if your first language is not English, to ensure that the academic content of 
your paper is fully understood by journal editors and reviewers, is optional. Language editing 
does not guarantee that your manuscript will be accepted for publication. For further 
information on this service, please click here. Several specialist language editing companies offer 
similar services and you can also use any of these. Authors are liable for all costs associated with 
such services. 
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II. ONLINE SUBMISSION 
A. Online Submission Instructions 
Please note that submissions go directly through ScholarOne Manuscripts.  
Note: Before you begin, you should be sure you are using an up-to-date version of Internet 
Explorer. If you have an earlier version, you can download a free upgrade using the icons found 
at the bottom of the Instructions and Forms section of the online submission web site.  
B. Preparing Your Manuscript  
Please ensure that the required formats for text and figure submission are followed strictly. 
 
Follow the Instructions to Authors regarding the format of your manuscript and references. 
 
Figures can be saved in .jpg, .gif, .tif or .eps format, at 150 dpi resolution. When preparing 
figures, please make sure that any characters or numbers included in the figures are large enough 
to read on-screen. 
 
Prepare any other files that are to be submitted for review, including any supplementary material. 
The permitted formats for these files are the same as for manuscripts and figures. Other file 
types, such as Microsoft Excel spreadsheets and PowerPoint presentations, may be uploaded but 
will not be converted to .pdf format. 
 
When naming your files, please use simple filenames and avoid special characters and spaces. If 
you are a Mac user, you must also type the three-letter extension at the end of the filename you 
choose (e.g., .doc, .rtf, .jpg, .gif, .tif, .ppt, .xls, .pdf, .eps, .mov). Your manuscript should be in 
any version of Microsoft Word for Windows or Macintosh. If you use Microsoft Office 2007, 
please use the Save As feature to save files in "97-2003" format. 
 
i.) Logging into the Submission Site: 
 
1.  First, you will need to log in to the Nicotine & Tobacco Research online submission site, 
ScholarOne.  
 
2. If you know your login details (i.e., you have submitted or reviewed a manuscript in 
this journal before), use your User ID and Password to log on. (Your user ID will 
usually be your email address.) 
 
3. If you do not know your login details, check to see if you are already registered by 
clicking on the Forgot your password? button and following the on-screen 
instructions. If you are not already registered, you can register by clicking on the 
Create account button on the login screen and following the on-screen instructions. 
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4. If you have trouble finding your manuscripts or have other problems with your 
account, do not create another account. Instead, please contact the journal's editorial 
office. 
C. Submitting a New Manuscript  
To submit a new manuscript, go to the Author Center, click on Click here to submit a New 
Manuscript, and then follow the on-screen instructions. There are up to 7 steps for you to 
follow to submit your manuscript. You move from one step to the next by clicking on the Save 
and Continue button on each screen or back to the previous screen by clicking on the 
Previous button. Please note that if you click on the Back or Forward button on your browser, 
the information you have entered will not be saved. 
 
To return to the submission process at a later date, you can click on the manuscript title in the 
Unsubmitted Manuscripts section in your Author Center. You may like to have the original 
electronic file available so that you can copy and paste the title and abstract into the required 
fields. 
 
To Upload Your Files in the Author Center “File Upload” Page: 
 
1. Enter individual files using the Browse buttons and select the appropriate File type 
from the pull-down menu. The choices may vary from journal to journal but will 
always include a Main Document. Use this designation for your manuscript text. 
 
2. Upload your files by clicking on the Upload files button. This may take several 
minutes. (Files are automatically converted to .pdf format for peer review.) Click on 
the Save button to confirm the upload. Repeat these steps until you have uploaded 
all your files. 
 
3. If you have uploaded any figures or tables you will be prompted to provide 
figure/table captions and file tags that will link figures to text in the html proof of 
your main document. The appropriate file designation for figure files should be 
chosen from the File type drop-down menu. Similarly, select the correct file type for 
supplementary material. 
 
4. Once you have uploaded all your files, indicate the order in which they should 
appear in your paper. This will determine the order in which they appear in the 
consolidated pdf used for peer review. 
 
5. After the successful upload of your text and images, you will need to view and 
proofread your manuscript. Please do this by clicking on the blue html button or a 
pdf button. 
 
6. If the files have not been uploaded to your satisfaction, go back to the file upload 
screen where you can remove the files you do not want and repeat the process. 
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7. When submitting your manuscript, please enter your manuscript data into the 
relevant fields, following the detailed instructions at the top of each page. You may 
like to have the original word-processing file available so you can copy and paste the 
title and abstract into the required fields. You will also be required to provide email 
addresses for your co-authors, so please have these at hand when you log on to the 
site. 
 
8. When you are satisfied with the uploaded manuscript proof, click on Next, which 
will take you to the Review & Submit screen. The system will check that you have 
completed all the mandatory fields and that you have viewed your manuscript proof. 
It will also present you with a summary of all the information you have provided and 
give you a final chance to edit it. If there is a red cross next to any section, this will 
indicate that not all the fields have been filled in correctly. You may either go back to 
the relevant page or click the nearest Edit button. 
 
9. When you have finished reviewing this information, press Submit. It is not until this 
button is pushed that the manuscript and all of the associated information (i.e., 
contributing authors, institutions, etc.) is linked together and the manuscript is given 
a manuscript number. Once the manuscript is submitted, it is not possible to undo 
the submission. 
 
10. After the manuscript has been submitted, you will see a confirmation screen and 
receive an email confirmation stating that your manuscript has been successfully 
submitted. This will also give the assigned manuscript number, which is used in all 
correspondence during peer review. If you do not receive this, your manuscript will 
not have been successfully submitted to the journal and the paper cannot progress to 
peer review. If this is the case, your manuscript will still be sitting in the 
Unsubmitted Manuscripts section of your Author Center awaiting your attention. 
 
11. If you return to your Author Center, you will notice that your newly submitted 
manuscript can be found in the Submitted Manuscripts area. The Status section 
provides information on the status of your manuscript as it moves through the 
review process. 
D. Submitting a Revised Manuscript 
Log on to the online submission site as before and, in the Author Center, click on 
Manuscripts with Decisions. At the bottom of the screen, you will see those manuscripts that 
require a revision (or that have been revised). Create a revision of this manuscript by clicking on 
Create a Revision under Actions. You will now be able to see the editor and reviewer 
comments and will be able to respond to these. 
 
You will need to upload the files that constitute your revised manuscript. To facilitate the 
production process, it is essential that you upload your revised manuscript as a .doc, .rtf, or .tex 
file, and not in .pdf format. If you wish to finish this another time, you will find the manuscript 
in your 'Revised manuscripts in draft' list. 
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If you click on View comments/respond you will see the editor's letter to you together with 
the referees' comments. You may cut and paste your responses into the text areas at the bottom 
of the screen. 
E. Figure Files 
Your images are required as high-resolution .tif files (1200 dpi for line drawings and 300 dpi for 
colour and half-tone artwork). For useful information on preparing your figures for publication, 
go to http://art.cadmus.com/da/index.jsp. Please note that publication of your manuscript 
will not proceed until figures suitable for reproduction are received. 
F. Getting Help 
If you experience any problems during the online submission process please consult the 
Author's User Guide, which provides more detailed submission instructions and 'movie tutorials' 
explaining how to submit your paper. Alternatively, please contact the journal editorial office 
who will be pleased to assist you. 
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III. FIGURE GUIDELINES 
A. Preparing Figures 
This information is also available online here. 
 
1. Why use a figure? Do not include a figure unless it is the best way to present 
information. Tables and text description take less space, and often are a simpler way 
to present findings. Limit the use of multiple-pane figures and complex figures. 
 
2. Follow the instructions. Figures must conform to the journal’s guidelines before a 
manuscript can be accepted in final form and sent to production. Submitting figures 
in a nonpreferred format will delay or prevent publication. The acceptance date will 
reflect any delays related to unacceptable figure file. 
 
3. Create or reuse? Authors submitting a figure simply copied from a PowerPoint 
presentation or a poster most likely will be asked to re-create the figure for 
publication, resulting in delays in acceptance and publication. The journal editors 
recommend that you create a figure specifically for submission to Nicotine & Tobacco 
Research, based on these guidelines. 
 
4. Colour or black/white? Figures can be colour or black/white. Figures published in 
color in the print version of the paper will incur a publishing cost to the authors 
($600.00 per figure). Figures can be published in black/white in print but in colour 
online at no cost to authors. In this case, the downloadable PDF of the published 
article will include colour figures. A colour figure also should be understandable in 
grayscale (that is, in pure black and white or with gray shades), since the article is 
likely to be photocopied or printed in grayscale. 
  
20 
 
B. Figure Preferences 
The below figure will reproduce well. 
 
C. Excel Figures 
Creating your figures in Excel helps ensure that they will be reproduced correctly and legibly. Do 
not copy your Excel figures into the Word document of your manuscript. Instead, provide 
figures in a separate Excel file, with each figure in a separate worksheet. The worksheet labels 
for the figures should be: Figure 1, Figure 2...  
 
Do not simply use the Excel defaults for creating a figure. You will need to make changes in the 
figure to make it clear and easy to follow:  
 
1. Remove the gridlines.  
2. Consider adding data labels if the data are not included in a table. Make the 
background white. 
3. Remove the “border” around the chart area, so that only the x and y axes remain. 
4. Thicken the axis lines so that they are at least three times as thick as the default lines. 
5. Thicken any plotted lines so that they are at least as thick as the axis lines. Point the 
tick marks inward rather than outward, if possible. 
6. Do not use gradations of shading; instead, use fine-lined textures.  
7. Do not use tick marks on an axis with text labels rather than numbers.  
8. If your x-axis data labels are lengthy or numerous, do not use angled labels. Instead, 
consider reversing the axes so that the labels are horizontal on the y-axis.  
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D. Other Graphic Programs 
If you create figures in a program such as SigmaPlot or CorelDraw, you must export the file as 
.TIF or another file format listed below. The typesetters can work with figures in the following 
formats:  
 
• .TIF (Tagged Image Format File)  
• .DOC (Microsoft Word document)  
• .XLS (Microsoft Excel)  
• .PPT (Microsoft PowerPoint)  
• .PDF (Portable document format, Adobe)  
• .AI (Adobe Illustrator) 
• .WMF (Windows metafile)  
•  .PNG (Portable Network Graphics) 
 
The journal or publisher editors may request that you redraw the figure and export it again.  
Please follow the preferred style example and the guidelines under “Excel figures.”  
E. Order the Figures 
Number all figures consecutively, as they should appear in the text.  
F. Separate Files 
Submit a figure as a separate file; do not embed it in the main manuscript document. 
G. Figure Size 
Size the figure to the column or page width of the journal and set the resolution at 300 dpi or 
greater for color and grayscale and 600 dpi for pure black and white 
H. Microcharts 
The Journal encourages the use of microcharts (also called sparklines) where appropriate. They 
can save considerable space and can include data and a graphic element. Shareware software for 
microcharts is available at http://www.bestshareware.net/download/microcharts-
professional.htm. 
. 
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IV. COMPETING INTERESTS 
Declarations of Funding and Competing Interest for Nicotine & Tobacco Research 
 
Please visit the updated Declaration of Funding and Competing Interest here.  
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V. TRANSPARENCY AND OPENNESS GUIDELINES 
The Transparency and Openness Guidelines can be downloaded as a PDF here. 
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VI.  OFFPRINT ORDER FORM 
The Offprint Order Form can be downloaded as a PDF here. 
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VII. OTHER RESOURCES 
1. Archived SRNT Trainee Network webinars are limited to society members, but everyone 
can now access the slides and handouts from two key presentations:  
a. “An Introduction to Writing Scientific Articles on Tobacco Use,” presented by 
SRNT Past President John Hughes and Saul Shiffman. Access the slides from their 
2013 webinar.  
b. “Getting Published in N&TR,” presented by Editor-in-Chief Marcus Munafò and 
Managing Editor Margaret Searle. Access the slides and handout from their 2015 
webinar. 
2. Terminology  
The International Society of Addiction Journal Editors recommends against the use of 
terminology that can stigmatize people who use alcohol, drugs, other addictive substances or 
who have an addictive behavior. Click here for more information. 
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VIII. EDITORIAL OFFICE CONTACTS 
 
Marcus Munafò, PhD 
Editor-in-Chief 
marcus.munafo@bristol.ac.uk 
 
 
Margaret Searle 
Managing Editor 
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